CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Craig Primack stated in part: “In my experience of treating thousands of people, lasting results come from focusing on the individual, not just the condition. This simple belief has shaped the way ...

Now, these developments are NOT, NOT, NOT a death sentence for HIMS. For one thing, another GLP-1RA, liraglutide, will be off patent and become available on HIMS in 2025. It’s used in Victoza.

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a few setbacks ...

Hims will also offer liraglutide, another weight loss treatment. Shares of Hims rose 5% after this announcement, indicating that markets saw it as a positive development. However, can this ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic ...

“We find it incredibly unlikely a consumer would go to HIMS to buy any branded GLP-1 for $1,899/month.” Instead, analysts are waiting to see on how well the company’s generic liraglutide perform ...